Form 4: Rigel Pharmaceuticals Executive David A. Santos Sells Shares to Cover Tax Obligations

David A. Santos, EVP, Chief Commercial Officer of Rigel Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• David A. Santos, an executive at Rigel Pharmaceuticals, sold shares of the company's common stock on February 4th and 5th, 2025.
• The sales were executed to cover tax withholding obligations arising from the vesting of Restricted Stock Units.
• On February 4th, 2025, 2,125 shares were sold at a price of $20.921 per share.
• On February 5th, 2025, 1,796 shares were sold at a price of $21.926 per share.
• Following these transactions, Santos directly owns 51,704 shares of Rigel Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (sale of shares for tax obligations). It's neutral in sentiment as it doesn't indicate positive or negative developments for the company.

Positives

• The transactions are related to tax obligations from vesting of Restricted Stock Units, which indicates that the executive is receiving equity compensation.

Management Comments

• These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units.
• Such 'sales to cover' were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time.
• Upon vesting, these RSUs are treated as income, and executives are required to pay income taxes on the value of the shares.
• To cover these tax obligations, executives often sell a portion of the shares that vest.
• This practice is common across various industries and companies, including pharmaceutical companies like Amgen, Gilead Sciences, and Biogen.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Form 4, Rigel Pharmaceuticals, RIGL, David A. Santos, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation